FIELD: medicine.
SUBSTANCE: present group of inventions relates to medicine, namely to neurology, and concerns the treatment of such neurological conditions as Alzheimer’s disease, Huntington's disease or stroke. For this, cardiac glycoside oleandrin is administered in the dose range from 12 to 1200 mcg. Introduction of this drug in the specified dose range allows you to reach the concentration of oleandrin in the plasma in the range from 0.005 to 10 ng/ml, which, in turn, ensures the neuroprotective effect of the drug.
EFFECT: introduction of this drug in the specified dose range provides a neuroprotective effect of the drug.
29 cl, 13 ex, 7 dwg, 1 tbl
